£900K
TwinPath Ventures led the pre-seed round to help accelerate regulatory clearance and clinical validation for the company's sepsis prediction software.
"I’ve lived through sepsis twice. I know how quickly stability becomes a crisis and how much an earlier insight can change the outcome. With VIOSync we’re giving clinicians a trusted, explainable way to predict risk before symptoms emerge, enabling faster decisions and ultimately saving lives. This funding is a strong validation of our mission and will help us accelerate both regulatory approvals and clinical adoption."